Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Recruiting · NCT06989723 · Registry updated 2025-05-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | Digestive System Diseases, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, liver disorder, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 4 | 2025-05-25 | NCT06989723 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celltrion | 14 |
| Seoul National University Bundang Hospital | 114 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Seoul National University Bundang Hospital | Seongnam-si | South Korea | 17 |